These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1436 related items for PubMed ID: 8760593

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application.
    Chapoval AI, Nelson H, Thibault C, Penna C, Dean P.
    J Hematother; 1995 Dec 01; 4(6):571-7. PubMed ID: 8846018
    [Abstract] [Full Text] [Related]

  • 5. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
    Porter LE, Nelson H, Ethem Gecim I, Rice DC, Thibault C, Chapoval AI.
    Cancer Immunol Immunother; 1997 Dec 01; 45(3-4):180-3. PubMed ID: 9435868
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The bispecific antibody 500A2 x 96.5 targets T-lymphocytes activated in vivo with staphylococcal enterotoxin B (SEB) against CL62 melanoma cells in vitro.
    Reid IM, Lundy JK, Donohue JH.
    Surg Oncol; 1994 Oct 01; 3(5):279-85. PubMed ID: 7889221
    [Abstract] [Full Text] [Related]

  • 8. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
    Penna C, Dean PA, Nelson H.
    Cancer Res; 1994 May 15; 54(10):2738-43. PubMed ID: 8168104
    [Abstract] [Full Text] [Related]

  • 9. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
    Demanet C, Brissinck J, De Jonge J, Thielemans K.
    J Hematother; 1995 Oct 15; 4(5):363-8. PubMed ID: 8581370
    [Abstract] [Full Text] [Related]

  • 10. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G, Gückel B, Wallwiener D, Moldenhauer G.
    Clin Cancer Res; 1999 Jan 15; 5(1):171-80. PubMed ID: 9918216
    [Abstract] [Full Text] [Related]

  • 11. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
    Belani R, Weiner GJ.
    J Hematother; 1995 Oct 15; 4(5):395-402. PubMed ID: 8581375
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
    Reid I, Lundy J, Donohue JH.
    J Immunol; 1992 Apr 15; 148(8):2630-5. PubMed ID: 1532818
    [Abstract] [Full Text] [Related]

  • 13. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A, Stevenson GT, Glennie MJ.
    J Immunol; 1991 Jul 01; 147(1):60-9. PubMed ID: 1675655
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 16. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
    Csóka M, Strauss G, Debatin KM, Moldenhauer G.
    Leukemia; 1996 Nov 01; 10(11):1765-72. PubMed ID: 8892680
    [Abstract] [Full Text] [Related]

  • 17. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
    Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R.
    Cancer Res; 2012 Aug 15; 72(16):3958-66. PubMed ID: 22745368
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH, Gratama JW, Warnaar SO, Stoter G, Bolhuis RL.
    Int J Cancer; 1995 Feb 08; 60(4):450-7. PubMed ID: 7829257
    [Abstract] [Full Text] [Related]

  • 19. Superantigen-activated T cells redirected by a bispecific antibody inhibit vesicular stomatitis virus replication in vitro and in vivo.
    Fernandez-Sesma A, Peluso RW, Bai X, Schulman JL, Levy DE, Moran TM.
    J Immunol; 1998 Feb 15; 160(4):1841-9. PubMed ID: 9469445
    [Abstract] [Full Text] [Related]

  • 20. Induction of antitumor immunity after cure of pulmonary metastases, using staphylococcal enterotoxin B and bispecific antibody.
    Rice DC, Chapoval AI, Porter L, Nelson H.
    Cancer Immunol Immunother; 1999 Aug 15; 48(5):230-8. PubMed ID: 10478639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.